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Abstract  46 
Objective: Translational endometrial cancer (EC) research benefits from an in vitro 47 
experimental approach using EC cell lines. We demonstrated the steps that are 48 
required to examine estrogen induced proliferative response, a simple yet important 49 
research question pertinent to EC and devised a pragmatic methodological workflow 50 
for utilising EC cell lines in experimental models. 51 
Methods/materials: Comprehensive review of all commercially available EC cell lines 52 
was carried out, and Ishikawa cell line was selected to study the estrogen 53 
responsiveness with HEC1A, RL95-2 and MFE280 cell lines as comparators where 54 
appropriate, examining relevant differential molecular (steroid receptors) and 55 
functional (phenotype, anchorage-independent growth, hormone responsiveness, 56 
migration, invasion and chemosensitivity) characteristics in 2D and 3D cultures in vitro 57 
using immunocytochemistry, immunofluorescence, qPCR and western blotting. In vivo 58 
tumour, formation and chemosensitivity were also assessed in a chick chorioallantoic 59 
membrane (CAM) model.  60 
Results: Short Tandem Repeat (STR) analysis authenticated the purchased cell lines 61 
while gifted cells deviated significantly from the published profile. We demonstrate the 62 
importance of prior assessment of the suitability of each cell line for the chosen in vitro 63 
experimental technique. Prior establishment of baseline, non-enriched conditions was 64 
required to induce a proliferative response to estrogen. The CAM model was a suitable 65 
in vivo multi-cellular animal model for EC, for producing rapid and reproducible data. 66 
Conclusions: We have developed a methodological guide for EC researchers when 67 
using endometrial cell lines to answer important translational research questions 68 
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(exemplified by estrogen responsive cell proliferation), to facilitate robust data, while 69 
saving time and resources.      70 
Keywords : Endometrial cancer, cell lines, estrogen 71 
  72 
6 
 
Introduction 73 
Endometrial cancer (EC) is the fourth commonest malignancy in women in Europe 74 
(6% of all female cancers) [1, 2]. The increasing rates of obesity are projected to 75 
increase EC incidence by up to 100% by 2025, relative to the observed incidence in 76 
2005 in some European countries [3]. EC-associated mortality has increased by 15% 77 
with many patients unsuitable for standard surgical treatment due to co-morbidities 78 
and 1 in 4 women experiencing serious surgical complications [4-6]. Current 79 
therapeutics also fail to treat late stage disease and, similar to ovarian cancer, survival 80 
rates are especially poor for advanced EC [7]. Despite all of the above, compared with 81 
other hormonally driven malignancies such as breast or ovarian cancer, EC is a 82 
relatively under-researched area. Further research, therefore, is urgently needed to 83 
formulate effective preventative and treatment modalities.  84 
The advancement of cancer therapy is dependent on the understanding of the 85 
pathogenesis associated molecular biology, which in turn is reliant on the availability 86 
of model systems. For basic science research, cell lines offer a relatively cheap and 87 
high-throughput model for screening potential biomarkers and therapeutic targets in a 88 
relatively quick and reproducible manner. Over 80% of ECs are carcinomas, and the 89 
first EC cell line HEC-1 was established in 1968 [8].  90 
The cell line that best represents the in vivo physiology and pathology of ECs can be 91 
determined by employing many phenotypic and functional characteristics. Due to the 92 
nature of continuous culture, potential contamination and spontaneous mutations can 93 
occur in these cell lines [9], representing a major potential confounding factor affecting 94 
experimental outcomes. The aim of this paper is to demonstrate how a pertinent 95 
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research question in EC cancer can be answered in vitro using an endometrial cell 96 
line, with a selective methodological process that we developed.  97 
Using the established epithelial EC cell line, Ishikawa (ISK), and three other 98 
established, commercially available and commonly used EC cell lines as required, we 99 
illustrated how the important EC function, estrogen induced cellular proliferative 100 
response could be a model in vitro. In doing so we developed a methodological guide 101 
that can be employed to model some known features of EC, (1) estrogen induce 102 
proliferation, characterising the differential molecular phenotype (hormone receptor 103 
expression (ERα, ERβ, AR, PR)) and functional properties (gene expression and 104 
proliferation) in vitro; and (2) chemosensitivity, illustrating the importance of initially 105 
establishing the basic functional features of the cell line (anchorage-independent 106 
growth, migration, and invasion in vitro and tumour formation in vivo in CAM). Our 107 
methodological guide will aid researchers considering using endometrial cell lines for 108 
their research.  109 
Materials and Methods  110 
Extended methods can be found in the supplementary methods section. 111 
Cell lines:  112 
Four established, endometrial cell lines; ISK, HEC1A [10] and RL95-2 [11] [12] and 113 
MFE280 [13] were selected and sourced from reputable commercial biobanks (ATCC 114 
and Public Health England (PHE)); which routinely screen their cell lines for 115 
contamination and genetic abnormalities. Furthermore, a highly passaged HEC1A cell 116 
line which was sourced from a collaborator was also used.  117 
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STR Profile Analysis 118 
DNA was extracted using the Wizard SV Kit (Promega, Southampton, UK) according 119 
to the manufacturer's protocol and sequenced using Promega Powerplex® 16 System, 120 
for tissue culture strain identification. Profile results were compared with published 121 
STR profiles for each cell line from ATCC, PHE Culture collections. 122 
Cell Culture 123 
All reagents were supplied by Sigma, Dorset, UK unless otherwise stated, cell lines 124 
were maintained in DMEM/F12 medium supplemented with 10% (v/v) fetal bovine 125 
serum (FBS, Biosera, UK), L-glutamine and penicillin/streptomycin benzyl penicillin at 126 
37oC in a 5% (v/v) CO2 atmosphere and details of cell line maintenance and 127 
modifications relevant to different assays are detailed in the supplementary methods 128 
section.  129 
Immunostaining 130 
Immunocytochemistry: Cells were grown in 8-well glass slide chambers until at least 131 
60% confluent, washed with PBS and fixed with 10% (v/v) Neutral Buffered Formalin 132 
(NBF) and permeabilized with 0.2% (v/v) Triton X-100 (BD Biosciences, Oxford, UK) 133 
in PBS. 3 µm-thick paraffin sections of tumour samples grown on CAM were prepared 134 
for immunostaining as previously described [14].  135 
Immunofluorescence: Unspecific antigens were blocked with 2.5% normal horse 136 
serum and incubated with primary antibodies overnight at 4oC. Cells were washed and 137 
incubated with the secondary antibodies for 1h in the dark (antibodies used detailed 138 
in Supplementary methods, and (Supplementary Table.. S6). Samples were then 139 
mounted (Vectorshield and Dapi mounting media (Vector Labs)) and visualised with 140 
an Eclipse 50i microscope (Nikon) using a mercury lamp. NIS-Elements F software 141 
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and ImageJ were used for image capture. For confocal images, fast Nipkow disc-142 
based confocal imaging attached to a high sensitivity (iXon Andor) CCD camera was 143 
used at the same intensity and compared with IgG controls. 144 
RNA Extraction and Real Time-qPCR 145 
RNA was extracted, quantified and reverse transcribed according to previously 146 
described method [15]. cDNA was amplified using iTaq Universal SYBR Green 147 
Supermix and the CFX Connect Real-Time System (Bio-Rad, Hercules, CA). Primers 148 
and reaction conditions are listed in Supplementary Table S5. Relative transcript 149 
expression was calculated by the ΔΔCT method, normalised to the reference genes 150 
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Zeta 151 
(YWHAZ) as previously described [15] and Peptidylprolyl Isomerase A PPIA [16] using 152 
Bio-Rad CFX Manager (Bio-Rad, Hertfordshire). Modified ERβ cDNA amplification 153 
step detailed in supplementary methods.  154 
Protein extraction and SDS-PAGE  155 
Protein lysates were prepared, quantified and analysed by SDS-PAGE as described 156 
previously [15] for the phosphorylated antibodies. For total ERα blots, samples were 157 
sonicated, and lysates were diluted in x5 Lammeli buffer, electrophoresed through 158 
10% (w/v) polyacrylamide gels. Primary antibodies used were phospho-estrogen 159 
receptor α (ERα antibody sampler kit (#9024, Cell Signalling, MA), anti-ERα (Abcam) 160 
validated against tubulin (Sigma: for ERα) or anti-glyceraldehyde 3-phosphate 161 
dehydrogenase (GAPDH). by densitometry using ImageJ [17] 162 
Assay for Cell Viability and Proliferation 163 
Cell viability and proliferation was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-164 
diphenyltetrazolium bromide) assay as previously described [18]. Cell viability was 165 
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expressed as a percentage of the untreated control. Experiments were run in triplicate 166 
with eight technical replicate wells. 167 
Scratch Migration Assay 168 
Linear scratch was made through each confluent monolayer (after overnight 169 
attachment) in 6- well plates, and perpendicular guidelines were drawn on the 170 
underside of the plate intersecting the scratch at 3 points per well. The wells were 171 
washed with PBS after the scratch, to remove any suspended cells, then medium 172 
was gently reapplied.  Images were taken at each guideline at 0h, 4h, 6h, 24h and 173 
48h and analysed using MiToBio software plugin [19] for ImageJ [17]. 174 
Chorioallantoic Membrane Model 175 
ISK, and HEC1A cells were labelled with an EGFP-expressing lentivirus donated by 176 
Dr Sokratis Theocharatos (University of Liverpool, UK). RL95-2 cells were labelled 177 
with a lentivirus expressing tGFP (pGFP-C-shLenti plasmid) (Origene, MD, USA), and 178 
selected using puromycin antibiotic selection. ISK and HEC1A viral transfection and 179 
egg preparation were performed according to Carter et al. 2012 [20]. Cells were added 180 
to the CAM at embryonic day 7 (E7) [21] the resulting tumours were imaged at E14, 181 
using a standard Leica M165-FC fluorescent microscope, in situ and after excision. 182 
(Fig. 5C) the resulting tumours were fixed in 10% (v/v) NBF and embedded in paraffin 183 
wax.  184 
Statistical Analysis 185 
Statistical analyses was performed using GraphPad Prism software using 186 
independent sample t-test to determine the difference between hormone regulation 187 
and transwell migration experiments. The criterion for significance was p≤0.05. Data 188 
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are presented as mean ± standard error of the mean (SEM).  MTT, scratch and FACS 189 
analysis analysed using independent samples t-test.  190 
Results 191 
Selection of the appropriate cell line(s) 192 
Figure S1 illustrates all currently available endometrioid EC cell lines that are available 193 
for researchers worldwide from commercial suppliers. We focussed on hormone 194 
responsive endometroid (or type 1) EC, to establish an in vitro model to examine 195 
estrogen induced proliferative response. Therefore, we selected the ISK cell line, 196 
which is known to express the full complement of steroid receptors, and three further 197 
cell lines (HEC1A, MFE280, and RL95-2) that originated from endometrioid tumours 198 
and exhibit a range of differentiation and hormone receptor expression, as 199 
comparators to ISK to illustrate different experimental approaches with alternative cell 200 
lines. Cell line details are in Supplementary Fig. S7. 201 
Authenticating cell lines 202 
As expected, the STR profile of the 4 commercially obtained cell lines exhibited their 203 
published profile (Supplementary Table. S2) [22] initially and at the end of our 204 
experimental process only with a few minor peaks indicating the beginnings of genetic 205 
drift but well within the 80-100% profile match (example in Fig. 1). However, the gifted 206 
HEC1A cell line (sourced 25 years ago, estimated to be passaged for more than 30 207 
times) deviated significantly from the published profile, with the omission and addition 208 
of multiple peaks, and cannot therefore be reliably used as HEC1A cells for 209 
comparison to other studies using the validated HEC1A cells (Fig. 1A). 210 
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Characterisation of the cell lines; 211 
Morphology  212 
The 4 selected cell lines were characteristically epithelioid in 2D culture (Fig. 1B), 213 
although the RL95-2 cell line exhibited a strong tendency to pile up in gland-like dome 214 
structures [23] with time in culture rather than form confluent monolayers like Ishikawa 215 
and HEC1A. The MFE 280 cell line tended to form discrete islands of cell clusters and 216 
presumably reflects that they were originally grown as aggregates in suspension 217 
culture [13]. In 3D culture with Matrigel, ISK (Fig. 1C), HEC1A and RL95-2 produced 218 
spheroids (Fig. 5B). There was no evidence of lumen formation under the culture 219 
conditions (Fig. 1C IV). 220 
Designing the experiment 221 
ISK cells expressing the full complement of steroid receptors was selected for testing 222 
our primary focus, modelling estrogen induced cell proliferation in EC. Comparisons 223 
were made between ISK and RL95-2 cells for most of the subsequent experiments 224 
considering the growth and the steroid hormone expression pattern. More invasive 225 
HEC1A cells (yet with a similar 2D growth pattern) were also examined in the migration 226 
and invasion experiments. 227 
Target Modulation  228 
Estrogen is the main driver of EC, and through modifying the expression of the other 229 
steroid receptors it modulates the general steroid responsiveness in EC cells, thus 230 
was our molecular target; therefore herein we demonstrate the characterization of ER 231 
expression (Fig. 2 & Supplementary Fig. S3) and the subsequent pharmacological 232 
manipulation of ER using the main naturally occurring ligand (E2) in the ISK cell line.  233 
13 
 
Hormone Regulation 234 
Estrogen is known to drive EC cell proliferation through ERα, therefore ERα mRNA 235 
and protein expression was confirmed in the ISK cell line (Fig.2-A-2C). ERα mRNA 236 
(ESR1) and protein were also expressed by MFE280 while low/undetectable mRNA 237 
and protein levels were observed in RL95-2 and HEC1A (Fig. 2A & 2C). All four cell 238 
lines retained detectable mRNA and protein for the ERβ subtype (Fig.1A). The 239 
expression of other hormone receptor gene/protein was also examined, demonstrating 240 
that the ISK cell line express mRNA and protein for all four steroid receptors (ERα, 241 
ERβ, AR and PR) compared with the other three cell lines (Fig. 2A - 2D).  242 
In ISK cells, the concentration of E2 and charcoal stripped FBS (CSFBS) were the 243 
main variables determining the proliferative response to estrogen. E2 increased ERα 244 
protein and it was phosphorylated on multiple serine residues (Fig. 2F & 245 
Supplementary Fig.S3A) in response to a range of E2 concentrations after 72h 246 
treatment (10-12-10-6M; Supplementary Fig. S3). In response to E2 binding, human 247 
ERα is predominately phosphorylated on Ser-118 and to a lesser extent on Ser-104 248 
and Ser-106 [24]. A physiologically relevant dose of E2, 10-8M was selected for the 249 
subsequent experiments. E2 (10-8M), up-regulated the known E2 regulated gene, PR 250 
mRNA by 24h (Fig. 2G), as expected. Supplementing the medium containing 10% 251 
FBS with estrogen did not augment BrdU incorporation (Supplementary Fig. S3B & 252 
S3C). FBS, stripped of steroid hormones by charcoal (CSFBS), was used in 253 
subsequent experiments in order to elicit an estrogen-dependent proliferative 254 
response. Cells were maintained in CSFBS for at least 48 hours prior to challenging 255 
with estrogen in CSFBS. Of the fetal bovine concentrations tested only 2% CSFBS 256 
with estrogen had a biologically significant dose dependent effect on proliferation as 257 
assessed by MTT assay (Fig. 2E & Supplementary Fig. S3D). This was preferable to 258 
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using the serum free medium which changed ISK morphology, detaching from the 259 
monolayer and significantly compromised the cell survival. Unless for a very short-260 
duration experiments (<12h) we did not find serum-free conditions to be suitable. 261 
Chemosensitivity  262 
Doxorubicin is a chemotherapy drug used to treat many types of cancer. The cytotoxic 263 
effect of doxorubicin on ISK and RL95-2 cells was examined to ascertain, the most 264 
suitable concentration to use in the CAM model. The IC50 for doxorubicin on ISK cells 265 
after 72h treatment as assessed by MTT assay was approximately 0.2µM (Fig. 3A). 266 
Spheroids of ISK in 3D cultures disintegrated with 0.1µM doxorubicin treatment for 267 
seven days (Supplementary Fig. S4) and this was associated with an increase in 268 
active caspase 3 levels (Fig. 3A). The IC50 for RL95-2 after 96 hours was 269 
approximately 0.03µM. (Fig. 3B). After 72h treatment, no IC50 was reached for RL95-270 
2 as assessed by MTT assay. With 1µM Doxorubicin treatment the MTT analysis 271 
showed significant differences between time points, (p<0.0001), FACS analysis also 272 
demonstrated a 60% reduction of the live cell population after 72h treatment with 10µM 273 
of doxorubicin as a secondary method to assess the cytotoxic effect of doxorubicin on 274 
RL95-2. Both assays showed similar effects on viability (Fig. 3B & 3C).   275 
Assessing changes functional characteristics 276 
Cell proliferation, migration and invasion are commonly evaluated functional attributes 277 
in cancer research. However, the exact experimental method suitable for each cell line 278 
may vary, therefore further optimisation is required. 279 
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Assessing changes in cell migration and invasion in vitro and in vivo 280 
Cell proliferation can be assessed in vitro using experimental methods such as BrdU 281 
incorporation (Supplementary Fig. S3), MTT assay, FACS analysis (Fig. 3B & 3C) as 282 
we have already demonstrated in sections above.  283 
Migratory ability  284 
Migration of cancer cells to seed extra-uterine sites, giving rise to metastatic lesions, 285 
is an important feature and can be assessed in vitro with the ‘scratch’ or ‘transwell’ 286 
assays [25]. Our optimisation of the scratch assay demonstrated the importance of 287 
prior knowledge of the 2D growth of cells. Scratch assay depended on the 288 
growth/migration of the cells in a horizontal plane, thus was only suitable for ISK and 289 
HEC1A cells. RL95-2 and MFE280 were unable to close the scratch even after 72h. 290 
Instead, they displayed a multi-layered growth of cells growing on top of the adherent 291 
monolayer (Fig. 4D). Therefore, to illustrate the utility of this method to assess 292 
migration, we compared ISK with HEC1A cells and developed an ImageJ-based 293 
analysis of the percentage reduction of the scratched area. In HEC1A the scratched 294 
area was recovered within 48h, whereas the ISK cells still had 40% of the scratch area 295 
exposed after 48h (Fig. 4A+4B). 296 
We then illustrated migration using transwells, an alternative technique, and compared 297 
HEC1A cells with RL95-2 cells. HEC1A cells readily migrated through the transwell 298 
membrane without preconditioning, whereas preconditioning was required for RL95-2 299 
migration. Under similar conditions, the HEC1A cells migrated at an increased rate 300 
compared with RL95-2 cells (Fig. 4E+4F).  301 
Invasion 302 
In vivo assessment of invasion 303 
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The invasion and metastatic ability of cancer cells can be ideally assessed in a 304 
multicellular in vivo system, and here we demonstrate the use of a relatively 305 
inexpensive, reproducible and rapid animal model system to examine EC cell invasion. 306 
Similar to the above in vitro migratory studies, cells of different invasive potential, ISK, 307 
HEC1A and RL95-2 were tested in vivo by growth in the CAM model for seven days, 308 
demonstrating a clear difference between the generated-tumours (Fig. 5B). ISK cells 309 
grew as sheets on CAM with no invasion or induction of neovascularisation determined 310 
by visualising chick vasculature within tumours. In contrast, large, macroscopic 311 
tumours were produced by both HEC1A and RL95-2 cells inducing a visible complex 312 
of tumour-associated blood vessels (Fig. 5B). We also demonstrate that the 313 
chemosensitivity of the tumours generated can be tested in this model where 72h 314 
treatment from day 11-14 with doxorubicin on the visible RL95-2-generated tumours 315 
affected viability, decreased proliferation (Ki67), and increased apoptosis (Bcl-2, Bax) 316 
as observed on tissue sections of paraffin-embedded samples (Fig. 5D). 317 
Discussion  318 
We demonstrate that EC cell lines could be utilised to model the important in vivo 319 
features of EC cells, a proliferative response to E2 in vitro. In doing so, we also 320 
developed a practically useful methodological flow chart (Fig. 6), to identify the best 321 
EC cell line to answer different research questions. We believe that initial use of this 322 
flow chart; will ensure selection of the best cell line, and most appropriate methodology 323 
to produce robust data, while saving time and resources. Our work underscored three 324 
important areas that are vital steps in vitro studies using EC cell lines; (1) 325 
authentication of the cell line, (2) prior establishment of pre-conditioning requirements 326 
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to elicit a response in an individual cell line, and (3) establishing baseline 327 
characteristics and growth pattern.  328 
In vitro culture of primary human endometrial epithelial cells from normal and 329 
carcinomatous tissue is a challenging process; consequently, the number of 330 
established EC cell lines that are currently commercially available to all researchers 331 
worldwide is also limited, and there is a complete absence of model normal/benign 332 
human endometrial epithelial cell line(s). 333 
Authentication of the cell lines, using STR profiling ensures that the features of the cell 334 
line have not changed, particularly when they are obtained from other sources than 335 
the reputable, authenticity guaranteed suppliers. We highlight the importance of initial 336 
genomic characterisation by demonstrating a significant genetic drift in the old HEC1A. 337 
This could be due to the cross-contamination with other cell lines, which has become 338 
a prolific problem throughout the world, with an alarming estimation that 15% of cell 339 
lines utilised in the USA to be either misreported or contaminated with other cell lines 340 
[26]. Although the scientific community is slowly combating the problem, caution needs 341 
to be taken when interpreting results from publications that have not authenticated the 342 
cell lines used. In the context of EC research, over the last decade, at least six 343 
publications used the so-called hormone responsive hTERT-EEC cell line, which was 344 
the misidentified breast cancer cell line MCF-7 [27-30]. Although the classical 345 
proliferative response to estrogen is seen in breast and endometrial tissue, the two 346 
tissues have very different responses to some other hormonal agents such as 347 
progestogens and tamoxifen [31, 32]. Therefore, the presumed clinical relevance of in 348 
vitro studies using hTERT-EEC may not have been completely relevant to the 349 
endometrium. This example highlights the importance of fully understanding the model 350 
being used. Obtaining cell lines from authorised cell banks, which authenticate cell 351 
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lines prior to purchase, will alleviate concerns of receiving misidentified cells whilst 352 
confirming the profile remains static throughout the study and at the end of the 353 
experimental period is also important.  354 
The published literature is sparse in describing the indispensable steps in assessing 355 
proliferative response to hormones (E2) of EC cell lines in vitro, such as 356 
preconditioning of the cells [33]. ERα was still phosphorylated in the presence of 10% 357 
FBS with E2, but the proliferative response was only observed at  lower CFBS 358 
concentrations. Our results are in keeping with the findings of Holinka et al. [33]. The 359 
baseline levels of ERα phosphorylation were different with CSFBS and FBS that 360 
demonstrates the importance of establishing baseline conditions with which to 361 
compare the treatment response, without masking them by endogenous agents within 362 
the culture model. Under normal culture conditions, EC cell proliferation depends on 363 
FBS to provide the essential growth factors, amino acids, etc., therefore, unless the 364 
cells are established in a baseline, non-enriched conditions prior to the experimental 365 
process, they are unable to demonstrate the total response to the growth stimuli such 366 
as E2. Cells have to be initially maintained under optimal growing conditions and then 367 
primed (CSFBS) prior to challenge (E2). Furthermore, FBS is an unknown entity with 368 
dramatic differences between batches with unquantified concentrations of the 369 
components. Therefore, it is important to conduct all experiments using the same 370 
batches of FBS to reduce variability across experimental replicates. Using CSFBS to 371 
maintain cell viability during the experimental process will reproducibly prime the cells 372 
to respond to the hormonal treatment, however, sub-optimal conditions might select 373 
for cells with reduced nutrient requirements. Thus, our work highlights the importance 374 
of the optimal preconditioning for the cell line of choice in endometrial research, for 375 
translational research in hormone modulation studies in vitro. 376 
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Examining cell lines for the essential apparatus to respond to a signal of interest is 377 
pivotal and our work demonstrated the importance of characterising the cell lines for 378 
the expression of ERα before further functional studies. Since even the high grade 379 
advanced ECs retain some hormone responsiveness [16], in vitro or in vivo models 380 
that mimic them are important in EC research.  381 
MTT assays work under the assumption that only living cells will be able to metabolise 382 
the MTT into formazan, however several other parameters such as the drugs used, 383 
the components of the culture medium can alter the metabolism as well as viability in 384 
these assays [34]. However, they do offer a quick, low-cost indirect method to assess 385 
cell death or cell proliferation to prompt further investigation. However, we recommend 386 
confirmation using another method that is not reliant on cell metabolism. FACS offers 387 
a multifaceted tool in which multiple parameters can be assessed depending on the 388 
dyes used.  389 
In our migration experiments, we demonstrated that the initial identification of the 390 
growth pattern of a suitable cell line dictates the potential subsequent experimental 391 
plan. We assessed cellular functionality using several methods considering the cell 392 
line specific differential growth pattern, for example, the scratch assay was only 393 
suitable for cells that grow in a horizontal 2D plane. The migratory ability of cells is an 394 
important factor when studying the metastatic spread, facilitating discovery of novel 395 
therapeutics. Transwell assay was suitable for the RL95-2 cells which displayed multi-396 
layered 2D growth but required strict adherence to protocol to reduce variance. 397 
Therefore, initial assessment of the exact growth conditions and patterns for each of 398 
the cell lines being studied is vital to obtain reproducible data.  399 
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Many animal models have been employed to assess cancer-associated angiogenesis 400 
and metastasis in vivo.  Of these, the CAM model has the advantage of being a 401 
relatively cheap, widely available, rapid and high throughput model and although it has 402 
been previously used to assess metastasis and invasion in ovarian cancer cell lines 403 
[35] and benign endometrial tissue [36], we have used this model in the context of EC 404 
cell lines for the first time. Upon inoculating onto the CAM, the EC cell lines would be 405 
severely depleted of growth factors and would not survive long unless the cells invade 406 
into the CAM and establish a vascular supply using the host (chick) vasculature, 407 
therefore the assessment of the cell viability and apoptosis within these newly formed 408 
tumours will reflect the potential aggressiveness of the EC cells. Harvested tumour 409 
established on the CAM can be analysed for markers of proliferation or apoptosis with 410 
IHC or qPCR. We have illustrated that in this model, the well-differentiated ISK cell 411 
line which showed lower invasive features in vitro, was unable to produce significant 412 
tumours whereas the less differentiated HEC1A and RL95-2 cells with more invasive 413 
in vitro behaviour produced large tumours with an impressive neo-vascularisation.  414 
Conclusions 415 
Cell lines offer a unique platform to gain insight into the molecular processes occurring 416 
in vivo; however careful selection of cell lines is important not only to be able to 417 
extrapolate the data into the clinical context but to compare with the previous and 418 
future studies. From the perspective of EC research, due to the limited in vitro capacity 419 
of primary cells, they can be used initially for rapid, reproducible discovery projects 420 
without relying on precious yet typically heterogeneous patient tissue. We have shown 421 
that essential feature of EC, estrogen induced proliferation can be demonstrated with 422 
necessary precondition steps in ISK cell line and we propose a pragmatic 423 
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methodological guide that will facilitate robust data generation in projects using cell 424 
lines, which saves time and resources.      425 
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Figure Legends 540 
Figure 1. A) STR profiles for gifted HEC1A and ATCC sources HEC1A cells with 541 
electropherograms for both analyses, illustrating an example of stutters in brackets, 542 
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omitted peaks in italics and additional peaks underlined compared with the published 543 
profile. B) Micrographs of Ishikawa (ISK), HEC1A, RL95-2 and MFE 280 cells in 544 
culture. C i) ISK grown in Matrigel™ ii) ISK grown in Matrigel™ stained with DAPI iii) 545 
Cross-section images of ISK spheroid grown in Matrigel™ stained for pan cytokeratin 546 
(PanCK) and iv) DAPI showing the filled spheroid structure. 547 
Figure 2. Hormone receptor expression. A) Estrogen receptor α (ERα), Estrogen 548 
receptor β (ERβ), Progesterone receptor (PR) and Androgen receptor (AR) mRNA 549 
expression by qRT-PCR in the four endometrial cancer cell lines; Ishikawa (ISK), 550 
HEC1A, RL95-2 and MFE280 B) ERα and ERβ expression using antibody staining by 551 
IHC and IF in the ISK cell line. C) The expression of ERα protein using western blot 552 
for the cell lines ISK, HEC1A, RL95-2 and MFE280. D) PR and AR expression in 4 553 
cell lines determined by IHC, positive staining shown by brown colour counterstained 554 
with haematoxylin (blue). Nuclear detection of the receptors was the criterion for being 555 
called positive or negative expressing. E) MTT assay: ISK cell proliferation was 556 
induced by 10-8M E2 or EGF treatment for 72h; E2 induced a marginal increase in 557 
proliferation with 5% CSFBS whilsta substantial induction of proliferation was 558 
observed when media containing 2% CSFBS was used, However, no response was 559 
observed with E2 treatment in the presence of 10% FBS. Statistical analysis using an 560 
independent sample t-test ****= p<0.0001, *= p<0.05. EGF treatment was used as a 561 
positive control. F) ERα total and phosphorylated protein increased in ISK cell line with 562 
treatment of 10-8M 17β-estradiol (E2) for 72h. G) mRNA level of PR after treatment 563 
with 10-8M E2 compared with vehicle  t-test ***= p<0.005.   Similar to the benign normal 564 
endometrial epithelial cells [37] and the low grade EC [16] the well differentiated ISK 565 
cell line expressed mRNA and protein for all 4 steroid receptors (ERα, ERβ, AR and 566 
PR) studied. The less well differentiated RL95-2 and MFE280 cell lines exhibited 567 
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loss/heterogeneous pattern of nuclear AR and PR, whilst more invasive, moderately 568 
differentiated HEC1A cell line also showed loss of AR and PR. These data illustrates 569 
the differences between each of the cell lines that potentially provide appropriate 570 
models to simulate various differentiation stages of EC in the laboratory. 571 
Figure 3. A) Percentage survival of ISK cells treated with Doxorubicin (DOXO) 572 
(0.01,0.1 and 1µM) for 72h in 2D growth, and 3D culture in Matrigel™ treated with 573 
0.1µM DOXO and Vehicle (V) for 72h. IF stained spheroid treated with doxorubicin 574 
shows increased activated caspase 3 (red color counterstained with DAPI). Western 575 
blot showing increased activated caspase 3 in doxorubicin treated cells. . B) Dose 576 
response of RL95-2 cell line to DOXO treatment from 24-96h of treatment with a range 577 
of doses 0.0001-10µM compared to control cells treated with V (DMSO) each time 578 
point using MTT assay. With DOXO treatment at 1µM showed significant differences 579 
between 24h and 96h. C) FACS analysis of 7-AAD and Hoechst 33342 dual stained 580 
RL95-2 cells treated with 1μMDOXO or V (DMSO), showed significant changes in the 581 
percentage of live, necrotic and dead cell populations. Data shown as percentage of 582 
cells detected per quadrant compared to single stained controls. Error bars represent 583 
SEM. Significance was determined using t-test. ****= p<0.0001, **= p <0.005 and *= 584 
p <0.05. 585 
Figure 4. A) Scratch area measured at set time points after scratch in ISK and HEC1A 586 
cell lines. 6 replicates per time point and error bars indicate SEM. B) Representative 587 
images of scratch closure images from 0-48h. The HEC1A cell line completely 588 
recapitulated the scratch area between 24-48h whereas ISK had not C) Example 589 
segmentation image of the MitoBio ImageJ plug in analysis to measure scratch area 590 
on ISK. D) MFE280 cell line grew upward around scratch edges preferring to grow on 591 
top of one another making measurement along the horizontal plane unrepresentative 592 
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of the cell lines migratory capacity. RL95-2 cells took much longer to form confluent 593 
monolayers (requiring larger number of cells to be plated) and the edges of the scratch 594 
would lift away from the plate surface. Tranwell migration was used to assess RL95-2 595 
migration in comparison with HEC1A. E) Number of HEC1A and RL95-2 cells that 596 
migrated through a transwell insert after 24h incubation after 16h preconditioning in 597 
serum free media toward a 10% FBS chemoattractant in cell line media ( t-test 598 
**p=0.0024). F) Image of inverted transwell insert after cells have migrated through 599 
the membrane. 600 
Figure 5. 3D culture models. A) Timeline for Chorioallantoic Membrane Model (CAM) 601 
assay. E0 indicates day eggs were incubated in the hatchery. At E3 excess albumen 602 
removed using an egg punch and a sterile syringe allowing windows to be cut in the 603 
uppermost side of the egg shell. At E7 CAMs were inoculated with cell lines and 604 
incubated for a further 7 days. For drug or vehicle control treatments Eggs were 605 
injected into the chorioallantoic sac at E11 and E13 with either DMSO (4μL/egg) or 606 
Doxorubicin (3μM) diluted in PBS. At E14 tumours were imaged and excised, fixed in 607 
10% NBF and paraffin wax embedded. B) HEC1A, ISK and RL95-2 grown on CAM. 608 
C) Cell lines grown in Matrigel™ D) IHC of excised tumours of RL95-2 tumours grown 609 
in CAM model sectioned and stained for Ki67, Bax and Bcl-2 after treatment for 72h 610 
with Doxorubicin (DOXO) or DMSO (V) as vehicle control. 611 
Figure 6. Example workflow for endometrial cancer cell line projects. Tumour weight 612 
refers to mice studies rather than CAM. 613 
 614 
 615 
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Supplementary Figure Legends 616 
Supplementary Table S1. List of commercially available cell lines of endometrioid 617 
origin, cell lines of unverifiable origin were excluded and additional information was 618 
added from source databases. Adapted from Barretina et al. 2012 [17] and populated 619 
with additional information from the internet search of commercial suppliers of cell 620 
lines. Source; American Type Culture Collection (ATCC), German Collection of 621 
Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen 622 
und Zellkulturen GmbH) (DSMZ), Japanese Collection of Research Bioresources Cell 623 
Bank (JCRB), Bioresources of RIKEN (RIKEN) and The European Collection of Cell 624 
Cultures (ECACC). Cell lines of unknown tissue origin were excluded. 625 
Supplementary Table S2. STR profiles for the endometrial cancer cell lines; HEC1A-626 
COL and HEC1A-ATCC, Ishikawa (ISK), RL95-2, MFE280 cell lines after completion 627 
of experiments to confirm the cell line identities. Peaks which are additional to the 628 
published profile are in green and omitted peaks are in red. Profile matches from 3 629 
STR profile databases (DSMZ, ATCC and the location the cells were sourced from) 630 
are shown for each cell line. 631 
Supplementary Figure S3. 17β-Estradiol (E2) effect on ERα and phospho-ERα. A) 632 
Western blot of phosphor-ERα (Ser118) after 72h E2 treatment at a range of 633 
concentrations 10-6-10-9M with a GAPDH control. B) BrdU incorporation with 4h 634 
treatment of 10-8M E2 with 5% charcoal stripped FBS (CSFBS). C) Example images 635 
of BrdU incorporation in response to E2 with DAPI counterstaining. ISK cells grown in 636 
DMEM:F12, phenol-red free media with 5% CSFBS 5x103 cells seeded per well in 8 637 
well slide chamber with vehicle or E2 10-8M (Sigma) for 2 h. BrdU (5’bromo-638 
2’deoxyuridine, #B5002, Sigma) added to make 10µM concentration. Incubated at 639 
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37oC for 4 h. Cells washed with PBS and fixed with 10% NBF. Cells denatured with 640 
2M HCl for 1 h, washed in borate buffer and blocked with 2.5% normal horse serum 641 
(Vector labs) for 30 min at room temperature. BrdU incorporation detected using 642 
Mouse monoclonal anti-BrdU antibody 1:200 incubated overnight and followed by 643 
Alexa Fluor 488 secondary antibody incubation. Cells were then washed and mounted 644 
using Vectashield with DAPI (Vector labs). D) Ishikawa cell treated with 10-8M E2 in 645 
media supplemented with 5% Charcoal Stripped FBS assessed for proliferative 646 
response by the MTT assay. Showing no proliferative response to E2 compared with 647 
vehicle (V), EGF used as a positive control. The 5% CSFBS media was not able to 648 
prime the cells to respond to E2 detected by BrdU incorporation or MTT assay. 649 
Supplementary Figure S4. Ishikawa cells grown in Matrigel™ treated with either 650 
vehicle, or with increasing doses of Doxorubicin (0.01μM, 0.1μM, 1μM) for 3 days and 651 
stained with DAPI. ISK tumour spheres were viably unaffected with 0.01μM 652 
Doxorubicin treatment, but some disaggregation of the tumour spheres started to 653 
occur at 0.1μM dose and the spheres completely disintegrated with 1μM Doxorubicin 654 
treatment..  655 
Supplementary Table S5. PCR Primer Table. Including primer sequences as provided 656 
by the literature cited, amplicon size in base pairs, primer efficiency and a publication 657 
or source reference. 658 
Supplementary Table S6. Antibodies Table. *Heat induced antigen retrieval by 659 
pressure cooking in citrate buffer pH 6. 1 Ely, Cambridgeshire, UK; 2 Cambridge, UK ; 660 
3 Oxford, UK ; 4 Newcastle upon Tyne, UK 5 Dorset, UK ; 6Hitchin, Hertfordshire, UK. 661 
O/N = Overnight, ICC= Immunocytochemistry, WB= Western Blot. 662 
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Supplementary Table S7. Table of Cell Line Characteristics for Ishikawa, HEC1-A, 663 
RL95-2 and MFE280. Hormone Receptor Status determined by immunohistochemical 664 
staining (Figure 2.). Doubling time determined by Goto et al 2008 [38], Kuramoto and 665 
Nishida 2012 [39], Way et al. 1983 [11], and DSMZ MFE280 cell line datasheet [40]  . 666 
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Supplementary Table S2. 723 
 724 
Lab/Published STR Profile 
Loci OLD HEC1A NEW HEC1A ISK RL95-2 MFE280 
A X X X X X 
D5S818 11,14,15 11,12,14,15 10,11,12 10,11 11,12 
D13S317 11,12,13 11,12 9,12 8,12 10,12 
D7S820 9,11 9,11,12 9,10 10 9,10 
D16S539 12,13 12,13 9 11,12,13,14 11,12 
vWA 18,19 18,19 14,17 16,19,20 16, 17 
TH01 6,7 6,7 9,10 9,9.3 7 
TPOX 8,11 8,11 8 8 9,10 
CSF1PO 10,12 10,12 11,12 10,11 8,9,11,12 
EV DSMZ 
profile 
database 
0.83 0.95 0.91 0.92 1.0 
% Match 
ATCC STR 
database 
78% 94% n/a 100% n/a 
Source 
Website STR 
information 
n/a 
ATCC (94% 
Match, 2 
small 
additional 
peaks and 1 
ommited 
peak) 
ECACC (1 
additional 
small peak) 
ATCC (3 small 
additional 
peaks) 
Sigma (100% 
Match) 
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